Johnson & Johnson has received FDA approval for a new treatment called Rybrevant Faspro. This treatment is for people with a specific type of lung cancer called EGFR-mutated non-small cell lung cancer. The new treatment is given as an injection under the skin, instead of through an IV in the vein. This means the treatment now takes just five minutes, instead of several hours. This makes it more convenient for patients and uses fewer healthcare resources. The approval is based on results from a study called PALOMA-3. This study showed that the new treatment met important health goals. The study results were first presented at a big medical meeting and published in a medical journal. More data from the study showed that the under-the-skin treatment, when combined with another drug called Lazcluze, helped patients live longer, respond better to treatment, and delayed the cancer’s progress compared to the IV treatment. At one year, 65% of patients receiving the under-the-skin treatment were alive, compared to 51% of those receiving the IV treatment. Biljana Naumovic, who leads the solid tumor medicine division at Johnson & Johnson, said: ‘The approval of Rybrevant Faspro is a big step forward. Patients with this type of lung cancer have had limited treatment options. Now, they have greater access to this transformative treatment and tools to manage common skin side effects.’ The side effects of the new treatment combined with Lazcluze were similar to those of the IV treatment. Common side effects included muscle and bone pain, bleeding, decreased appetite, and nerve problems. Recently, Johnson & Johnson agreed to buy Halda Therapeutics for $3.05 billion in cash.